Showing 1411-1420 of 1537 results for "".
Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Natural Products that Exhibit Antifungal Activity
https://practicaldermatology.com/topics/general-topics/natural-products-that-exhibit-antifungal-activity/20360/Can natural products fight the fungus among us?Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20513/Psychodermatology: A Review
https://practicaldermatology.com/topics/practice-management/psychodermatology-a-review/21180/Psoriasis, Biologics, and Cardiovascular Disease: The Heart of the Matter
https://practicaldermatology.com/topics/psoriasis/psoriasis-biologics-and-cardiovascular-disease-the-heart-of-the-matter/23215/A relationship between increased cardiovascular events in patients with psoriasis has implications for management of this chronic disease.JAK Inhibitors in Hidradenitis Suppurativa: A Systematic Review
https://practicaldermatology.com/topics/feature/jak-inhibitors-in-hidradenitis-suppurativa-a-systematic-review/29887/Hidradenitis suppurativa (HS) is a chronic, disfiguring, debilitating, inflammatory disorder that is characterized by inflammatory nodules, abscesses, fistulae/ sinus tracts, and scarring to the axilla, inframammary folds, and groin.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who h